Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.2010721296855
   PubMed Web of Science ®Google Scholar
• Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018;30(1):1–12. doi:10.21147/j.issn.1000-9604.2018.01.0129545714
   PubMed Web of Science ®Google Scholar
• Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer–report of a Canadian multicenter randomized trial. J Clin Oncol. 1988;6(4):633–641. doi:10.1200/JCO.1988.6.4.6332833577
   PubMed Web of Science ®Google Scholar
• Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22(2):330–353. doi:10.1200/JCO.2004.09.05314691125
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–98. doi:10.1056/NEJMoa01195411784875
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Baker S, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27(36):6251–6266. doi:10.1200/JCO.2009.23.562219917871
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi:10.1056/NEJMoa081069919692680
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol. 2007;25(12):1545–1552. doi:10.1200/JCO.2005.05.147417442998
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(25):5892–5899. doi:10.1200/JCO.2005.02.84016043829
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu Y-L, Yu C-J, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(30):5080–5087. doi:10.1200/JCO.2008.21.554119738125
   PubMed Web of Science ®Google Scholar
• Jian H, Li W, Ma Z, et al. Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status. Sci Rep. 2017;7(1):8483. doi:10.1038/s41598-017-08399-828814805
   PubMedGoogle Scholar
• La Salvia A, Rossi A, Galetta D, et al. Intercalated chemotherapy and epidermal growth factor receptor inhibitors for patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer. 2017;18(1):23–33 e1. doi:10.1016/j.cllc.2016.08.00627876230
   PubMed Web of Science ®Google Scholar
• Rocco G, Nason K, Brunelli A, Varela G, Waddell T, Jones DR. Management of stage IIIA (N2) non-small cell lung cancer: a transatlantic perspective. J Thorac Cardiovasc Surg. 2016;151(5):1235–1238. doi:10.1016/j.jtcvs.2016.01.03526997100
   PubMed Web of Science ®Google Scholar
• Patel AP, Crabtree TD, Bell JM, et al. National patterns of care and outcomes after combined modality therapy for stage IIIA non-small-cell lung cancer. J Thorac Oncol. 2014;9(5):612–621. doi:10.1097/JTO.00000000000015224722151
   PubMed Web of Science ®Google Scholar
• Bunn PA Jr. Future directions in clinical research for lung cancer. Chest. 1994;106(6 Suppl):399S–407S. doi:10.1378/chest.106.6_supplement.399s7988273
   PubMed Web of Science ®Google Scholar
• Group NM-AC. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561–1571. doi:10.1016/S0140-6736(13)62159-524576776
   PubMed Web of Science ®Google Scholar
• Rosell R, Gómez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330(3):153–158. doi:10.1056/NEJM1994012033003018043059
   PubMed Web of Science ®Google Scholar
• Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86(9):673–680. doi:10.1093/jnci/86.9.6738158698
   PubMed Web of Science ®Google Scholar
• Wu Y-L, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013;14(8):777–786. doi:10.1016/S1470-2045(13)70254-723782814
   PubMed Web of Science ®Google Scholar
• Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e314S–e340S. doi:10.1378/chest.12-236023649445
   PubMed Web of Science ®Google Scholar
• Robinson LA, Ruckdeschel JC, Wagner H, Stevens CW. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):243S–265S. doi:10.1378/chest.07-137917873172
   PubMed Web of Science ®Google Scholar
• Pisters KMW, Vallières E, Crowley JJ, et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010;28(11):1843–1849. doi:10.1200/JCO.2009.26.168520231678
   PubMed Web of Science ®Google Scholar
• Zhong W, Yang X, Yan H, et al. Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status. J Hematol Oncol. 2015;8:54. doi:10.1186/s13045-015-0151-325981169
   PubMed Web of Science ®Google Scholar
• Kim L, Saieg M, Di Maio M, et al. Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. Oncotarget. 2017;8(34):57528–57536. doi:10.18632/oncotarget.1572528915692
   PubMedGoogle Scholar
• Douillard J-Y, Ostoros G, Cobo M, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014;9(9):1345–1353. doi:10.1097/JTO.00000000000026325122430
   PubMed Web of Science ®Google Scholar
• Kimura H, Suminoe M, Kasahara K, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer. 2007;97(6):778–784. doi:10.1038/sj.bjc.660394917848912
   PubMed Web of Science ®Google Scholar
• Salto-Tellez M, Tsao M-S, Shih J-Y, et al. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. J Thorac Oncol. 2011;6(10):1663–1669. doi:10.1097/JTO.0b013e318227816a21869714
   PubMed Web of Science ®Google Scholar
• Yatabe Y, Kerr KM, Utomo A, et al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. J Thorac Oncol. 2015;10(3):438–445. doi:10.1097/JTO.000000000000042225376513
   PubMed Web of Science ®Google Scholar